RealTime Dynamix™: Multiple Sclerosis (US) Q4 2018 Spotlight
With the announcement by Alkermes and Biogen that Alkermes has submitted an NDA to the FDA for Vumerity (diroximel fumarate; BIIB098), there are now two disease-modifying therapies (DMTs) with potential 2019 launches for the treatment of relapsing forms of MS (RMS). The second DMT, whose NDA resubmission was accepted by the FDA in July 2018, is EMD Serono’s Mavenclad (cladribine tablets). Although both are potential treatments for RMS, awareness, familiarity, and interest among US neurologists (n=100) vary widely for these two pipeline DMTs.
The two DMTs are also slated to be used at different points in the RMS treatment algorithm. Insights from the Mavenclad prelaunch section in the most recent RealTime Dynamix: Multiple Sclerosis (US) report suggest a later line role for Mavenclad among DMT-refractory RMS patients with aggressive disease activity. Vumerity, on the other hand, will most likely be used earlier in the treatment algorithm in Tecfidera candidates where avoidance of tolerability issues is key. View complimentary data highlights from the full report below.
Contact [email protected] for more information about the highlighted report or to see if your company already has access to the report series.
All company, brand or product names and logos in this document are trademarks of their respective holders.